Mark Jackson has been appointed vice president of Quality for Noven Pharmaceuticals Inc. Read More »

The U.S. Food and Drug Administration approved Amgen's Parsabiv for the treating of secondary hyperparathyroidism in adults with chronic kidney failure and is administered at dialysis locations throughout the country. Read More »

Charles Holley Jr. has joined the Amgen Board of Directors as a member of the Audit Committee and the Corporate Responsibility and Compliance Committee.  Read More »

Florida Hospital and Walgreens have initiated a retail health clinic and pharmacy collaboration to focus on delivering coordinated care and providing greater access to patients across the Tampa region. Read More »

Biopharmaceutical company Amgen won a major victory in case involving the infringement of two patents held by the company. Read More »

A $1.15 per share dividend was recently declared by Amgen's Board of Directors for the first quarter of next year. Read More »

Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »

Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of Acanthamoeba Keratitis. Read More »

Amgen presented data from its Phase 3 TOWER study at the 58th Annual Meeting and Exposition of the American Society of Hematology this week in San Diego. Read More »

Amgen will partner with Janssen Biotech to assess the drug combination made up of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen, over the course of multiple clinical trials for the treatment of patients who have multiple myeloma. Read More »

Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »

Amgen plans to partner with Janssen Biotech to further assess the drug combination of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen. Read More »

The National Pharmaceutical Council Board of Directors has appointed Dr. Joshua Ofman as its new vice chairman. Read More »

Amgen's results of its Phase 3 coronary intravascular imaging trial, call GLAGOV, will be presented at the American Heart Association Scientific Sessions 2016. Read More »

Amgen's Phase 3 clinical trial to assess XGEVA compared to zoledronic acid has achieved its primary goal of proving to delay the time to the first skeletal-related event on-study for multiple myeloma patients. Read More »

Amgen's Phase 3 erenumab clinical trial has turned in positive results. Read More »

The U.S. Food and Drug Administration has approved Amgen’s AMJEVITA for the treatment of seven different inflammatory diseases. Read More »

Amgen recently reported top-line results of its Phase 3 CLARION trial that was designed to assess KYPROLIS (carfilzomib), melphalan and prednisone (KMP), Amgen's new investigational regimen, while comparing it to Velcade (bortezomib). Read More »

Amgen has announced that the data from studies involving romosozumab and Prolia will be presented at the Annual Meeting of American Society for Bone and Mineral Research (ASBMR) on Sept. 16-19 in Atlanta, Georgia. Read More »

Amgen and Servier last week announced that their cardiovascular collaboration has seen an advancement due to Servier deciding to exercise its option for the commercialization of omecamtiv mecarbil in Europe for chronic heart failure. Read More »